US Stocks Move: ImmunityBio slumps on November 12 as Q3 results miss expectations, net loss widens, going concern doubts arise, and executives cash out
Bitget异动解读2026/11/12 15:31ImmunityBio November 12 Sell-off Analysis
Keywords: Q3 earnings double miss, net loss expansion, going concern doubts, executive share sales
1. On November 9, ImmunityBio released its Q3 2026 financial results: adjusted loss per share was $0.09, wider than the analyst expectation of a $0.08 loss; revenue stood at $48.841 million, below the expected $59.25 million—a gap of about 17.6%.
2. In Q3, GAAP diluted net loss per share was $0.18, a significant increase from $0.07 for the same period last year; net loss reached $184.6 million, compared to $67.3 million in the prior year.
3. Although revenue grew 52.3% year-on-year, quarterly product revenue fell versus the previous quarter. Growth was insufficient to meet high market expectations for ANKTIVA commercialization ramp-up.
4. The company stated that, absent additional financing, there are "substantial doubts" about its ability to continue as a going concern.
5. Over the past year, three directors collectively sold $9.51 million in shares, drawing attention to significant insider divestments.
(Disclaimer: This content is generated by AI using publicly available information for summary purposes only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. existing home sales fall to a 16-year low as high interest rates and inflation continue to suppress housing demand
In October, U.S. existing home sales declined by 5.5% month-on-month, with the annualized rate dropping to 3.75 million units, the lowest since 2010. In the Western region, sales fell to the lowest level since record-keeping began in 1999. Mortgage rates above 7% and persistently high inflation are the main reasons for this downturn. Meanwhile, existing home inventory for sale in October rose to the peak level seen in the same period of 2019, and price momentum has significantly weakened. According to the NAR chief, once interest rates turn around, suppressed homebuying demand could erupt all at once.
Crypto prices
More
